Adrex 17/1 CAN

Adrex 17/1 CAN

Product details


The Shishkaberry strain is made by crossing the DJ Short Blueberry strain with an Afghan strain. The name of the latter strain is not yet known.


Each batch of Adrex 17/1 CAN targets a THC level of 15.8% and a CBD level of less than 0.1%.

The cannabis plant is packed full of natural compounds. This includes cannabinoids (including THC and CBD), terpenes and flavonoids. The entourage effect refers to all of these compounds working together in synergy to enhance the effects of cannabis. The terpenes included in this strain are Myrcene, Limonene, and Ocimene. As with each individual cannabinoid, each terpene has its own range of benefits.


Storing your cannabis product correctly will prolong its life. Keep it in a cool, dry place and away from sunlight. It’s essential to keep this product (and any cannabinoid product) out of the reach of children and animals.

Dosing guidelines

The guidance provided here is not intended to be medical advice – patients will discuss their dosage guidelines with a medical professional independently before beginning their treatment.

Patients can choose to consume Adrex 17/1 CAN by mixing it in with their food or drink. Some people prefer this method as it avoids smoking or vaping, which will not be suitable for everyone’s medical needs. Depending on the patient’s body fat percentage, metabolism, height and weight, the effects can be felt within one or two hours and can last for ten hours. Inhalation is preferable for some patients thanks to the fast-acting nature of this method (between five and fifteen minutes.)

Lab Reports

ADREXpharma has all of its necessary licenses and is committed to safe medical cannabis treatment. The company ensure that all of their products undergo all of the necessary testing to ensure the efficacy and safety of the product.


It’s important to note here that this information is based on anecdotal research. While the current scientific literature is promising, there needs to be further peer-reviewed research published for more direct conclusions. Patients should contact their medical cannabis specialist if they are unsure about treatment.

Related Posts